Tag: Anti-PD-1

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

CHICAGO, December 19, 2023–(BUSINESS WIRE)–MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today announced dose selection for THIO-101, a Phase 2 clinical trial evaluating its lead asset, THIO, in sequential combination with Regeneron’s anti-PD-1 cemiplimab (Libtayo®) in patients with…

Continue Reading MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes | Antibodies

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes Details Category: Antibodies Published on Tuesday, 19 December 2023 09:37 Hits: 742 TROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoadjuvant treatment for early-stage triple negative and HR…

Continue Reading Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes | Antibodies

Brace yourselves for these trends in clinical research in 2024

There’s an air of cautious optimism about 2024, after a difficult few years following the end of the pandemic when investment in pharma and biotech research dropped substantially. After this significant reset, there’s now hope that in 2024, in line with emerging trends, the funds will be there for the…

Continue Reading Brace yourselves for these trends in clinical research in 2024

Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer

Lung cancer ICB cohort Advanced non-small cell lung carcinoma patients who were treated with anti-PD-1/PD-L1 monotherapy at Samsung Medical Center, Seoul, Republic of Korea were enrolled for this study. The present study has been reviewed and approved by the Institutional Review Board (IRB) of the Samsung Medical Center (IRB no….

Continue Reading Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer

Expert Guidelines Detail Optimal Sequencing of Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer, Journal Club

Read the Full Video Transcript Rashid Sayyid: Hello everyone and thank you for joining us in this UroToday recording. I’m Rashid Sayyid, the Urologic Oncology Fellow at the University of Toronto, and along with Zach Klaassen, Associate Professor Program Director at Wellstar MCG Health, we’ll be discussing the recently amended…

Continue Reading Expert Guidelines Detail Optimal Sequencing of Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer, Journal Club

FDA Approves Belzutifan for Adult Patients With Advanced RCC

This approval of belzutifan (Welireg) for the treatment of advanced renal cell carcinoma (RCC) is supported by findings from the phase 3 LITESPARK-005 study (NCT04195750). Statistically significant and clinically meaningful improvements in progression-free survival (PFS) were observed with belzutifan. This approval provides adult patients with RCC who progressed on immune…

Continue Reading FDA Approves Belzutifan for Adult Patients With Advanced RCC

Global DNA/RNA Extraction Industry aims for a consistent 7.4% CAGR during the period spanning 2023 to 2033 as per FMI’s analysis

PRESS RELEASE Published December 14, 2023 The global DNA/RNA extraction industry is on a trajectory of substantial growth, with estimations revealing promising projections. Future Market Insights’ latest report indicates that in 2022, the market boasted a value of US$ 1.3 billion, which surged to US$ 1.40 billion in 2023. Anticipated…

Continue Reading Global DNA/RNA Extraction Industry aims for a consistent 7.4% CAGR during the period spanning 2023 to 2033 as per FMI’s analysis

Amgen (AMGN) Announces FDA Grants Priority Review to Tarlatamab Application for Advanced Small Cell Lung Cancer

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company’s Biologics License Application (BLA) for tarlatamab. Tarlatamab is a potential first-in-class, investigational delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE®) therapy for the treatment of adult patients…

Continue Reading Amgen (AMGN) Announces FDA Grants Priority Review to Tarlatamab Application for Advanced Small Cell Lung Cancer

Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 in Combination with KEYTRUDA for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer -December 12, 2023 at 06:22 am EST

RAHWAY – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck s anti-PD-1 therapy,…

Continue Reading Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 in Combination with KEYTRUDA for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer -December 12, 2023 at 06:22 am EST

Comprehensive Review of Small Interfering RNAs (siRNAs)

Introduction Cancer, also called malignancy, is a group of diseases caused by the rapid multiplication and spread of malignant cells.1,2 According to statistics from the National Cancer Center, more than 100 types of cancer have been identified.3 The ability of malignant tumor cells to metastasize via the blood-lymphatic system and…

Continue Reading Comprehensive Review of Small Interfering RNAs (siRNAs)

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma

Li Z, Gao Y, Cao Y et al (2023) Extracellular RNA in Melanoma: advances, challenges, and opportunities. Front Cell Dev Biol 11:1141543. doi.org/10.3389/fcell.2023.1141543 Article  PubMed  PubMed Central  Google Scholar  Hamid O, Cowey CL, Offner M, Faries M, Carvajal RD (2019) Efficacy, Safety, and tolerability of approved combination BRAF and MEK…

Continue Reading RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma

Merck (MRK), Moderna (MRNA) initiate INTerpath-002 Phase 3 trial of V940/KEYTRUDA combo in NSCLC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment…

Continue Reading Merck (MRK), Moderna (MRNA) initiate INTerpath-002 Phase 3 trial of V940/KEYTRUDA combo in NSCLC

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

TOKYO, Dec 11, 2023 – (JCN Newswire) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced that the Phase 3 LEAP-001 trial evaluating LENVIMA®, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA®,…

Continue Reading Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

2023-12-08 | NYSE:MRK | Press Release

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, did not meet its dual primary endpoints of overall…

Continue Reading 2023-12-08 | NYSE:MRK | Press Release

r – How to perform t test and plot p-values for comparison between groups on a grouped boxplot (ggplot)?

I have a data frame, as shown below: > dput(filtered_lymph) structure(list(cluster = c(“CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”, “CD4+ Tcells”,…

Continue Reading r – How to perform t test and plot p-values for comparison between groups on a grouped boxplot (ggplot)?

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma -December 08, 2023 at 06:47 am EST

Merck and Eisai announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with…

Continue Reading Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma -December 08, 2023 at 06:47 am EST

Merck to stop phase 3 trial of Keytruda plus Lynparza for lung cancer patients

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Merck…

Continue Reading Merck to stop phase 3 trial of Keytruda plus Lynparza for lung cancer patients

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma, Business News

ROCKVILLE, Md. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating…

Continue Reading Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma, Business News

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma USA – English APAC – Traditional Chinese APAC – English

ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating…

Continue Reading Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma USA – English APAC – Traditional Chinese APAC – English

NOTCH1 mutations predict superior outcomes, NSCLC

Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, and the majority are non-small-cell lung cancer (NSCLC).1,2 Genetic variation is a typical feature of NSCLC that drives cancer initiation and progression.3 Understanding the role of mutated genes in NSCLC is the basis of the development of novel treatment…

Continue Reading NOTCH1 mutations predict superior outcomes, NSCLC

Targeting the epigenome to reinvigorate T cells for cancer immunotherapy | Military Medical Research

Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knöpper K, et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022;609(7926):354–60. Article  CAS  PubMed  PubMed Central  Google Scholar  Zhu L, Zhou X, Gu M, Kim J, Li Y, Ko CJ, et al. Dapl1 controls NFATc2…

Continue Reading Targeting the epigenome to reinvigorate T cells for cancer immunotherapy | Military Medical Research

Coherus and Junshi Biosciences Announce Publication of

– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1 status– – Treatment resulted in a 37% reduction in the risk of death versus chemotherapy alone – -– LOQTORZI is the…

Continue Reading Coherus and Junshi Biosciences Announce Publication of

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer

Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019;20:377–88. Article  CAS  PubMed  PubMed Central  Google Scholar  Li L, Papadopoulos V. Advances in stem cell research for the treatment of primary hypogonadism. Nat Rev Urol. 2021;18:487–507. Article  CAS  PubMed  Google Scholar  Lawrence…

Continue Reading Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer

H101 for cervical cancer | DDDT

Introduction Patients with persistent, recurrent, or metastatic (P/R/M) cervical carcinoma respond poorly to treatment despite the best available therapeutic regimens, with a 5-year survival of 17%.1 Most of them are heavily pretreated with chemotherapy and/or radiotherapy, and many patients experience complications related to treatment or advanced disease, which exclude them…

Continue Reading H101 for cervical cancer | DDDT

Pan-Cancer Analysis and Validation of Opioid-Related Receptors Reveals

Introduction The potential role of opioids used in oncology patients has been controversial. Epidemiological and retrospective studies have demonstrated that lower opioid doses and regional anesthesia (epidural, intrathecal, or paravertebral) for breast,1 colon,2 or melanoma3 are linked to lower rates of cancer recurrence, while general anesthesia with high opioid doses…

Continue Reading Pan-Cancer Analysis and Validation of Opioid-Related Receptors Reveals

Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

Junshi Biosciences SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced a new publication in the Lancet Infectious Diseases. The paper presents final analysis…

Continue Reading Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

Junshi Biosciences Announces Lancet Infectious Diseases

SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced a new publication in the Lancet Infectious Diseases. The paper presents final analysis results from…

Continue Reading Junshi Biosciences Announces Lancet Infectious Diseases

New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma

Late-breaking analysis from pivotal INDIGO Phase 3 trial demonstrates vorasidenib led to tumor shrinkage in IDH1/2-mutant diffuse glioma First data from Phase 1 trial show the safety and tolerability of vorasidenib plus KEYTRUDA® (pembrolizumab) in recurrent or progressive enhancing IDH1-mutant diffuse astrocytomas BOSTON, Nov. 18, 2023 /PRNewswire/ — New data from Servier’s…

Continue Reading New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma

Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines | Journal of Translational Medicine

Personalized medicine aims to revolutionize healthcare by providing tailored treatments based on an individual’s unique characteristics. Genetic information of the host and target plays a crucial role in determining disease susceptibility and treatment response [1, 2]. By utilizing genomic analysis, biomarker identification, risk assessment, tailored treatment strategies, and continuous monitoring,…

Continue Reading Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines | Journal of Translational Medicine

Personalized medicine: “Tyranny of the gene”

Dr Priya Hays, Ph.D., CEO/Science Writer at Hays Documentation Specialists, LLC, responds to “Tyranny of the Gene.” Is personalized medicine a threat to public health? Not really, but yes, it’s an argument for price controls and perhaps more regulations; we hear Tyranny of the Gene: Personalized Medicine’s Threat to Public…

Continue Reading Personalized medicine: “Tyranny of the gene”

Gholam Explores the Phase 3 RATIONALE-301 Study of Sorafenib in HCC

Pierre Gholam, MD, professor at Case Western Reserve University School of Medicine in Cleveland, Ohio, discusses the phase 3 RATIONALE-301 (NCT03412773) study of frontline tislelizumab (BGB-A317) vs sorafenib (Nexavar) for patients with hepatocellular carcinoma (HCC). The global, phase 3 RATIONALE-301 trial randomized 674 patients to receive tislelizumab, an IgG4 anti-PD-1…

Continue Reading Gholam Explores the Phase 3 RATIONALE-301 Study of Sorafenib in HCC

IO Biotech enrols 380 patients with advanced melanoma in phase 3 trial

The trial is evaluating an investigational cancer vaccine in combination with Keytruda IO Biotech has announced that it has completed the enrolment of 380 patients in a phase 3 clinical trial of its investigational immune-modulating therapeutic cancer vaccine in advanced melanoma. The open-label, randomised clinical study being…

Continue Reading IO Biotech enrols 380 patients with advanced melanoma in phase 3 trial

IO Biotech enrolls 380 Patients in phase 3 advanced melanoma trial

IO102-IO103 is an investigational immune-modulating therapeutic cancer vaccine designed to target immunosuppressive mechanisms. Metastatic melanoma is a life-threatening cancer and although many new treatments have been introduced over the last decade that have significantly improved the outcomes for patients, there remains a high unmet need for more efficacious options with…

Continue Reading IO Biotech enrolls 380 Patients in phase 3 advanced melanoma trial

Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses

Bladder cancer is the most prevalent cancer of the urological system and it is histologically and genomically heterogeneous, which results in highly variable outcomes. Although improved strategies, such as the introduction of Bacillus Calmette-Guerin (BCG) and cisplatin-based chemotherapy, have significantly improved prognosis, that of high-risk, advanced, and metastatic BCa remains…

Continue Reading Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

IO Biotech Trial expected to reach the primary endpoint of progression free survival in the second half of 2025 Per-protocol interim analysis expected in mid-2024 NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced today that…

Continue Reading IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Your weekly fix of the latest biotech news: November 10, 2023

You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under…

Continue Reading Your weekly fix of the latest biotech news: November 10, 2023

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla, Inc. Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be presented at upcoming IASLC conference in early December and discussed at KOL event on December 4, 2023 Observed new PRs with…

Continue Reading BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla to Participate in the Jefferies London Healthcare Conference

BioAtla, Inc. SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled…

Continue Reading BioAtla to Participate in the Jefferies London Healthcare Conference

Insights into expression patterns and immunotherapy response prediction

[1] D. Schadendorf, D. E. Fisher, C. Garbe, J. E. Gershenwald, J. Grob, A. Halpern, et al., Melanoma, Nat. Rev. Dis. Primers, 1 (2015), 15003. doi.org/10.1038/nrdp.2015.3 doi: 10.1038/nrdp.2015.3 [2] A. M. M. Eggermont, A. Spatz, C….

Continue Reading Insights into expression patterns and immunotherapy response prediction

Merck & Co., Inc. Announces Phase 3 Keynote-564 Trial Evaluating KEYTRUDA, Merck?s Anti-PD-1 Therapy -November 01, 2023 at 06:30 am EDT

Merck & Co., Inc. announced that the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck?s anti-PD-1 therapy, met its key secondary endpoint of overall survival (OS), for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection…

Continue Reading Merck & Co., Inc. Announces Phase 3 Keynote-564 Trial Evaluating KEYTRUDA, Merck?s Anti-PD-1 Therapy -November 01, 2023 at 06:30 am EDT

T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Hedrick, S. M., Cohen, D. I., Nielsen, E. A. & Davis, M. M. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308, 149–153 (1984). Article  CAS  PubMed  Google Scholar  Yanagi, Y. et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains….

Continue Reading T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Identification of hub genes associated with gastric cancer

Introduction GC is a common malignant tumor of digestive system. According to the International Agency for Research on Cancer (IARC) of the World Health Organization, there were 19.29 million new cancer cases and 9.96 million deaths worldwide in 2020, of which the number of new cases of GC was 1089,103…

Continue Reading Identification of hub genes associated with gastric cancer

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe, Business News

SHANGHAI, Oct. 25, 2023 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in Europe has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung…

Continue Reading First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe, Business News

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

SHANGHAI, Oct. 25, 2023 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in Europe has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung…

Continue Reading First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

Merck Announces Results from the Phase 3 KEYNOTE-A39 Trial -October 22, 2023 at 10:30 am EDT

Merck announced results from the Phase 3 KEYNOTE-A39 trial (also known as EV-302), which was conducted in collaboration with Seagen and Astellas, evaluating KEYTRUDA, Merck?s anti-PD-1 therapy, plus Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, compared to chemotherapy (gemcitabine plus cisplatin or carboplatin) in patients with previously untreated locally advanced or…

Continue Reading Merck Announces Results from the Phase 3 KEYNOTE-A39 Trial -October 22, 2023 at 10:30 am EDT

Merck shares positive results for Keytruda in early-stage breast cancer

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage trial of its anti-PD-1 therapy Keytruda (pembrolizumab) in certain breast cancer patients. The phase 3 KEYNOTE-756 study has been evaluating Keytruda in combination with chemotherapy as neoadjuvant treatment for surgical…

Continue Reading Merck shares positive results for Keytruda in early-stage breast cancer

Merck Reveals Positive Results From Phase 3 KEYTRUDA Trials In Various Cancers

Drug major Merck & Co., Inc. (MRK) Friday announced positive results of Phase 3 trials with its anti-PD-1 therapy KEYTRUDA (pembrolizumab) in various cancers. In the Phase 3 KEYNOTE-756 trial, KEYTRUDA in combination with chemotherapy showed statistically significant improvement in pathological complete response or pCR rate as neoadjuvant therapy versus…

Continue Reading Merck Reveals Positive Results From Phase 3 KEYTRUDA Trials In Various Cancers

BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)– BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR) and event-free survival (EFS) by…

Continue Reading BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)

Microbial-enrichment method enables high-throughput metagenomic characterization from host-rich samples

Tuganbaev, T. et al. Diet diurnally regulates small intestinal microbiome-epithelial-immune homeostasis and enteritis. Cell 182, 1441–1459 (2020). Article  CAS  PubMed  Google Scholar  Dejea, C. M. et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359, 592–597 (2018). Article  CAS  PubMed  PubMed Central  Google Scholar  Bullman,…

Continue Reading Microbial-enrichment method enables high-throughput metagenomic characterization from host-rich samples

Tislelizumab Could Be a First-Line Treatment for HCC

3D illustration of human liver: ©PIC4U – stock.adobe.com Tislelizumab (Tevimbra), an anti-PD-1 monoclonal antibody, demonstrated overall survival (OS) improvements vs sorafenib (Nexavar) in patients with unresectable hepatocellular carcinoma (HCC), according to a study published in JAMA Oncology.1 In the phase 3 RATIONALE-301 trial (NCT03412773), the median OS was 15.9 (95%…

Continue Reading Tislelizumab Could Be a First-Line Treatment for HCC

Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023

TOKYO, Oct 11, 2023 – (JCN Newswire) – Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2023, which is taking place virtually and in-person in Madrid, Spain from October…

Continue Reading Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131) Demonstrated favorable safety and tolerability with no SAEs, low incidence and no increase of infections vs….

Continue Reading Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Liquid Biopsy ctDNA Could Serve as Early Marker of Immunotherapy Response

Results from the first stage of a Phase II clinical trial suggest that measuring circulating tumor DNA (ctDNA) captured in blood-based liquid biopsies may help to identify those advanced non-small cell lung cancer (NSCLC) patients undergoing immunotherapy who could benefit from treatment with additional drugs. Data from this first stage…

Continue Reading Liquid Biopsy ctDNA Could Serve as Early Marker of Immunotherapy Response

Merck shares positive results for Keytruda in phase 3 bladder cancer study

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage trial of its anti-PD-1 therapy Keytruda (pembrolizumab) in certain bladder cancer patients. The phase 3 AMBASSADOR trial has been evaluating Keytruda versus observation as an adjuvant treatment for patients with…

Continue Reading Merck shares positive results for Keytruda in phase 3 bladder cancer study

Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells

Credit: CC0 Public Domain Cancer immunotherapy drugs called PD-1 inhibitors are widely used to stimulate the immune system to fight cancer, but many patients either don’t respond or develop resistance to them. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to…

Continue Reading Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells

Innovative strategies of reprograming immune system cells

Introduction Cancer is well characterized by genomic instability resulting in structural alterations that build up with tumor progression.1,2 A subpopulation of undifferentiated cancer cells, known as cancer stem cells (CSCs) are found within the tumor bulk. These cells are responsible for cancer initiation, recurrence and show therapeutic resistance and these…

Continue Reading Innovative strategies of reprograming immune system cells

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients with Certain Types of Metastatic Non-Small Cell Lung Cancer -September 25, 2023 at 10:05 am EDT

RAHWAY – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck‘s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain…

Continue Reading Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients with Certain Types of Metastatic Non-Small Cell Lung Cancer -September 25, 2023 at 10:05 am EDT

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). In a prespecified interim analysis,…

Continue Reading Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo

Merck, Eisai post Phase 3 setbacks for lung cancer therapy

wildpixel Merck (NYSE:MRK) and Eisai (OTCPK:ESALF) announced Friday that two Phase 3 trials designed to evaluate a drug regimen containing the U.S. drugmaker’s anti-PD-1 therapy Keytruda and Eisai’s (OTCPK:ESAIY) Lenvima in lung cancer did not meet their primary endpoints. The trials named LEAP-006 and LEAP-008 enrolled patients with certain types…

Continue Reading Merck, Eisai post Phase 3 setbacks for lung cancer therapy

Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets

Background: To date, standardising clinical predictive biomarkers for assessing the response to immunotherapy remains challenging due to variations in personal genetic signatures, tumour microenvironment complexities and epigenetic onco-mechanisms. Main body: Early monitoring of key non-coding RNA (ncRNA) biomarkers may help in predicting the clinical efficacy of cancer immunotherapy and come…

Continue Reading Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets

Merck & Co., Inc. Announces Phase 3 Keynote-A39/Ev-302 Trial Met Dual Primary Endpoints of Overall Survival (Os) and Progression-Free Survival in Certain Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer -September 22, 2023 at 06:00 am EDT

Merck & Co., Inc. announced positive topline results from the Phase 3 KEYNOTE-A39 trial (also known as EV-302), which was conducted in collaboration with Seagen and Astellas, evaluating KEYTRUDA, Merck?s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) versus chemotherapy (gemcitabine plus cisplatin or carboplatin) in patients with previously untreated…

Continue Reading Merck & Co., Inc. Announces Phase 3 Keynote-A39/Ev-302 Trial Met Dual Primary Endpoints of Overall Survival (Os) and Progression-Free Survival in Certain Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer -September 22, 2023 at 06:00 am EDT

Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

(RTTNews) – Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen Inc. (SGEN) and Astellas Pharma Inc. (ALPMY.PK, ALPMY). The trial evaluated KEYTRUDA, Merck’s anti-PD-1 therapy, in…

Continue Reading Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

Phase 3 trials of pembrolizumab plus lenvatinib in metastatic NSCLC miss primary endpoints

September 22, 2023 1 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading Phase 3 trials of pembrolizumab plus lenvatinib in metastatic NSCLC miss primary endpoints

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2023 Report Revealing the Latest Trends and Outlook for Advancements by 2030

The latest research report for the Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market (2023-2030) is divided into different types [ Chimeric antigen receptor (CAR) T cell therapy, Monoclonal anti-CD20 antibody, Monoclonal anti-PD-1 antibodies, Monoclonal anti-PD-L1 antibodies ] and applications [ Hospital, Clinic ]. This segmentation enables users to extract valuable…

Continue Reading Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2023 Report Revealing the Latest Trends and Outlook for Advancements by 2030

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market: Exploring Current Trends and Industry Dynamics

The “Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market” research study for 2023 delves deeply into market segmentation by Types [Monoclonal anti-CD20 antibody, Monoclonal anti-PD-1 antibodies, Monoclonal anti-PD-L1 antibodies], Applications [Hospital, Clinic, ], and regional dynamics. Under the market dynamics section, this detailed study illustrates the present market landscape, highlighting emerging…

Continue Reading Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market: Exploring Current Trends and Industry Dynamics

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer

Genomic analysis and cohort description We generated whole-exome sequencing (WES) and RNA sequencing (RNA-Seq) data from tumors and blood samples from 27 advanced urothelial cancer patients treated with anti-PD-1/PD-L1 ICIs at Hospital del Mar (Fig. 1a). WES data was obtained from the tumors before treatment as well as from blood samples,…

Continue Reading The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer

Pembrolizumab Plus Lenvatinib Fails to Meet Expectations in mCRC, Advanced Melanoma

The combination of pembrolizumab (KEYTRUDA), an anti-PD-1 therapy, plus lenvatinib (LENVIMA), a multiple-receptor tyrosine kinase inhibitor, failed to meet its primary end point of overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in a recent phase 3 trial. Moreover, the drugs’ manufacturers announced that they discontinued the phase…

Continue Reading Pembrolizumab Plus Lenvatinib Fails to Meet Expectations in mCRC, Advanced Melanoma

Immunotherapy Failure Linked to Intratumoral Heterogeneity

The results of a study led by researchers at EMBL’s European Bioinformatics Institute (EMBL-EBI), Cold Spring Harbor Laboratory (CSHL), and Massachusetts Institute of Technology (MIT), have shed light on why immune checkpoint blockade (ICB) immunotherapy does not always work in some cancers with a high tumor mutational burden (TMB). The…

Continue Reading Immunotherapy Failure Linked to Intratumoral Heterogeneity

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Insights Report 2023-2030 | 110 Pages Report

[110 Pages Report] “Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market” Market Size, Share and Industry Trends Analysis Report By Applications (Hospital, Clinic),Types (Chimeric Antigen Receptor (CAR) T Cell Therapy, Monoclonal Anti-CD20 Antibody, Monoclonal Anti-PD-1 Antibodies, Monoclonal Anti-PD-L1 Antibodies), By Regional Outlook and Forecast, 2023-2030. The report presents the research and…

Continue Reading Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Insights Report 2023-2030 | 110 Pages Report

Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease

Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease Company’s flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers than Fluzone HD Vaccine pipeline advancing rapidly with Company announcing the completion…

Continue Reading Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease

OSE Immunotherapeutics announces: positive ph

Nantes, France – September 11, 2023, 6:00pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the peer-reviewed publication in Annals of Oncology* of the randomized Phase 3 clinical trial (Atalante-1) on T-cell epitope cancer vaccine Tedopi® in HLA-A2 positive patients with advanced or metastatic NSCLC in monotherapy…

Continue Reading OSE Immunotherapeutics announces: positive ph

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Quantitative and Qualitative Analysis | Global Industry Developments, and Forecast to 2030 | with 97 Pages

Recent research on the “Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market” offers a thorough analysis of market growth prospects as well as current kinds [Chimeric antigen receptor (CAR) T cell therapy, Monoclonal anti-CD20 antibody, Monoclonal anti-PD-1 antibodies, Monoclonal anti-PD-L1 antibodies] and applications [Hospital, Clinic] segmentation trends on a worldwide scale….

Continue Reading Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Quantitative and Qualitative Analysis | Global Industry Developments, and Forecast to 2030 | with 97 Pages

Calcium electroporation of esophageal cancer induces gene expression changes: a sub-study of a phase I clinical trial

Ágoston D, Baltás E, Ócsai H, Rátka S, Lázár PG, Korom I et al (2020) Evaluation of calcium electroporation for the treatment of cutaneous metastases: a double blinded randomised controlled phase II trial. Cancers. doi.org/10.3390/cancers12010179 Article  PubMed  PubMed Central  Google Scholar  Alrumaihi F (2022) The multi-functional roles of CCR7 in…

Continue Reading Calcium electroporation of esophageal cancer induces gene expression changes: a sub-study of a phase I clinical trial

Regorafenib, nivolumab, chemo combo found safe and effective for various cancers, heading to phase 3 trial

Credit: Pixabay/CC0 Public Domain Researchers at Memorial Sloan Kettering Cancer Center, New York, have concluded their phase 2 trial of chemotherapy in combination with the drugs nivolumab, and regorafenib. The findings, “First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the U.S.: a single-arm,…

Continue Reading Regorafenib, nivolumab, chemo combo found safe and effective for various cancers, heading to phase 3 trial

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Booming Unveiling High-Growth Sectors 2023

“Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market| Outlook 2023-2028 | Pre and Post-COVID Research is Covered, Report Information | Newest 110 Pages Report The extent and overview of the various commercial opportunities throughout the ensuing years are shown in the global “Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market” research report,…

Continue Reading Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Booming Unveiling High-Growth Sectors 2023

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market – Growth, Trends and Forecast (2023

“Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market” is expected to witness significant growth in the coming years, primarily driven by the growing demand for (Hospital, Clinic), Based on the type, the market can be segmented into (Chimeric Antigen Receptor (CAR) T Cell Therapy, Monoclonal Anti-CD20 Antibody, Monoclonal Anti-PD-1 Antibodies, Monoclonal…

Continue Reading Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market – Growth, Trends and Forecast (2023

Multiplexed transcriptomic profiling of the fate of human CAR T cells in vivo via genetic barcoding with shielded small nucleotides

Wagner, A., Regev, A. & Yosef, N. Revealing the vectors of cellular identity with single-cell genomics. Nat. Biotechnol. 34, 1145–1160 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  Gehring, J., Hwee Park, J., Chen, S., Thomson, M. & Pachter, L. Highly multiplexed single-cell RNA-seq by DNA oligonucleotide tagging of cellular…

Continue Reading Multiplexed transcriptomic profiling of the fate of human CAR T cells in vivo via genetic barcoding with shielded small nucleotides

Janssen Seeks Full Approval for Balversa in FGFR3-Altered Bladder Cancer

NEW YORK – Janssen said on Monday that it is seeking full approval in the US for Balversa (erdafitinib) as a treatment for patients with FGFR3-altered locally advanced or metastatic urothelial carcinoma after progressing on an anti-PD-1/PD-L1 therapy in the metastatic setting or within a year of neoadjuvant or adjuvant…

Continue Reading Janssen Seeks Full Approval for Balversa in FGFR3-Altered Bladder Cancer

Propulsion of PD-1 Non-Small Cell Lung Cancer Clinical Trial Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Domain

PRESS RELEASE Published August 28, 2023 (Albany, United States) As per DelveInsight’s assessment, globally, the PD-1 Non-Small Cell Lung Cancer Pipeline constitutes 30+ key companies continuously working towards developing 30+ PD-1 Non-Small Cell Lung Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and…

Continue Reading Propulsion of PD-1 Non-Small Cell Lung Cancer Clinical Trial Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Domain

Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-010 Trial of KEYTRUDA pus LENVIMA

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, as a first-line treatment for patients…

Continue Reading Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-010 Trial of KEYTRUDA pus LENVIMA

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade

Introduction Immune checkpoint inhibitors (ICIs) have revolutionized the treatment pattern of various cancers, including melanoma and non-small cell lung cancer (NSCLC).1–3 However, there are still a considerable proportion (40%–60%) of patients who do not respond or do not achieve durable responses to these drugs.4 Thus, it is urgent clinical need…

Continue Reading Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade

Circio Holding ASA: First half 2023 results -Yesterday at 01:01 am| MarketScreener

Oslo, Norway, 24 August 2023 – Circio Holding ASA (OSE: CRNA),a biotechnology company developing novel circular RNA and immunotherapy medicines, today announces its first half 2023 results. Members of Circio’s executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below)….

Continue Reading Circio Holding ASA: First half 2023 results -Yesterday at 01:01 am| MarketScreener

PDS Biotechnology (PDSB) Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced the submission to the U.S. Food and Drug Administration (FDA) of an updated…

Continue Reading PDS Biotechnology (PDSB) Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

PDS Biotech Announces Submission of Phase 3 Protocol to FDA

VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and neck cancer PDS Biotech anticipates initiating the VERSATILE-003 trial in the fourth quarter of 2023 PRINCETON, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage…

Continue Reading PDS Biotech Announces Submission of Phase 3 Protocol to FDA

PDS Biotech Announces Phase 3 Trial for Promising Head and Neck Cancer Treatment

PDS Biotech, a leading biopharmaceutical company, has recently announced a significant development in their quest to combat head and neck cancer. They have submitted a Phase 3 protocol to the U.S. Food and Drug Administration (FDA) for the initiation of the groundbreaking VERSATILE-003 trial. This trial is set to explore…

Continue Reading PDS Biotech Announces Phase 3 Trial for Promising Head and Neck Cancer Treatment

PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

PDS Biotechnology Corporation Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the fourth quarter 2023 Biomarker data from VERSATILE-002 to be presented at ESMO 2023 Company to host conference call and webcast today at 8:00 AM EDT PRINCETON, N.J.,…

Continue Reading PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

Tempest Reports Second Quarter 2023 Financial Results and

BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2023 and provided a corporate update. “2023 continues to be a productive and…

Continue Reading Tempest Reports Second Quarter 2023 Financial Results and

Strategies to therapeutically modulate cytokine action

Cohen, S., Bigazzi, P. E. & Yoshida, T. Commentary. Similarities of T cell function in cell-mediated immunity and antibody production. Cell Immunol. 12, 150–159 (1974). Article  CAS  PubMed  Google Scholar  Keegan, A. D. & Leonard, W. J. in Paul’s Fundamental Immunology 8th edn, ch. 9 (eds Flajnik, M. F., Singh,…

Continue Reading Strategies to therapeutically modulate cytokine action

Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights – Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma – –   neoRanker™ immunogenicity prediction module of PELEUS™ increases the likelihood of identifying multiple memory T…

Continue Reading Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Reply to: Revisiting the intrinsic mycobiome in pancreatic cancer

Fletcher, A. A. et al. Revisiting the intrinsic mycobiome in pancreatic cancer. Nature doi.org/10.1038/s41586-023-06292-1 (2023). Aykut, B. et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature 574, 264–267 (2019). Article  ADS  CAS  PubMed  PubMed Central  Google Scholar  Alam, A. et al. Fungal mycobiome drives IL-33 secretion…

Continue Reading Reply to: Revisiting the intrinsic mycobiome in pancreatic cancer

Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification

Human study The study was approved by the institutional review boards (Ethics Commission of the Medical Faculty of Technical University Munich (protocol 193/17S) and Ethics Committee of the Medical Faculty of Heidelberg University (protocol S-206/2011)) and all patients provided written informed consent under these protocols. The study was conducted in…

Continue Reading Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification

BioAtla Reports Second Quarter 2023 Financial Results and

Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug Administration (FDA) meeting request for potentially registrational study of BA3011 in non-small cell lung cancer (NSCLC) study; FDA feedback and initiation of study…

Continue Reading BioAtla Reports Second Quarter 2023 Financial Results and

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy U.S. Food and Drug Administration approval represents a potential significant…

Continue Reading AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Merck’s Keytruda combination shows promise in late-stage breast cancer study

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its Keytruda (pembrolizumab) combination in certain breast cancer patients. The phase 3 KEYNOTE-756 trial has been evaluating the anti-PD-1 therapy in combination with chemotherapy as a neoadjuvant treatment…

Continue Reading Merck’s Keytruda combination shows promise in late-stage breast cancer study

What is Cancer immunotherapy targeting STING?

What is Cancer immunotherapy targeting STING?   What is Cancer immunotherapy targeting STING? Over the past decade, cancer immunotherapy using immune checkpoint inhibitors has achieved unprecedented success in cancer treatment; however, only a small fraction ( 10-35% ) of patients can derive clinical benefit from this treatment, Therefore, there is…

Continue Reading What is Cancer immunotherapy targeting STING?

Phase 3 RATIONALE-301 Study Evaluates Tislelizumab vs Sorafenib in HCC

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the phase 3 RATIONALE-301 trial (NCT03412773) which evaluated frontline tislelizumab vs sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC). In the RATIONALE-301 trial, tislelizumab demonstrated improved health-related quality of life, physical functioning, fatigue, and HCC symptom…

Continue Reading Phase 3 RATIONALE-301 Study Evaluates Tislelizumab vs Sorafenib in HCC

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer | Antibodies

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer Details Category: Antibodies Published on Friday, 28 July 2023 17:17 Hits: 194 KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus…

Continue Reading Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer | Antibodies

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

July 28, 2023 6:45 am ET KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy KEYNOTE-756 is the first positive Phase 3 study with an immunotherapy regimen to demonstrate a statistically significant improvement in pCR rate in the neoadjuvant setting for this patient…

Continue Reading Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

Merck and Moderna Initiate Phase 3 Study Evaluating V940 in Combination With Pembrolizumab for Resected Stage IIB-IV Melanoma

Merck and Moderna recently announced the initiation of their pivotal phase 3 V940-001 clinical trial evaluating V940 (mRNA-4157; Moderna), an investigational individualized neoantigen therapy, in combination with pembrolizumab (Keytruda; Merck), an anti-PD-1 therapy, as an adjuvant treatment for patients with resected high risk (stage IIB-IV) melanoma.1 The first patients are…

Continue Reading Merck and Moderna Initiate Phase 3 Study Evaluating V940 in Combination With Pembrolizumab for Resected Stage IIB-IV Melanoma

Phase 3 Trial Underway for Novel Pembrolizumab Combination for Treatment of High-Risk Melanoma

Merck and Moderna, Inc have announced the initiation of the phase 3, randomized V940-001 (NCT05933577) clinical trial, which is evaluating the safety and efficacy of pembrolizumab (Keytruda; Merck) plus the individualized neoantigen therapy (INT) V940 (mRNA-4157) as an adjuvant therapy regimen for patients with resected high-risk (stage 2B-4) melanoma, according…

Continue Reading Phase 3 Trial Underway for Novel Pembrolizumab Combination for Treatment of High-Risk Melanoma